Jose Wiley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jose Wiley has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Prakash Krishnan
Icahn School of Medicine at Mount Sinai
6 shared publications Robert Pyo
Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA
6 shared publications- Divyanshu Mohananey
Medical College of Wisconsin Cardiovascular Center , Milwaukee, WI
5 shared publications - Harish Ramakrishna
Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN
5 shared publications - Tanush Gupta
Division of Cardiology, University of Vermont Medical Center, Burlington, Vermont, USA
5 shared publications Anna Bortnick
4 shared publications
Latest Publications
- 1 December 2018
- Published by SAGE Publications in Vascular
- Vol. 27 (1) , 78-89
Bivalirudin versus heparin in patients undergoing percutaneous peripheral interventions: A systematic review and meta-analysis
Background: Bivalirudin may be an effective alternative anticoagulant to heparin for use in percutaneous peripheral interventions. We aimed to compare the safety and efficacy of bivalirudin versus heparin as the procedural anticoagulant agent in patients undergoing percutaneous peripheral intervention. Methods: For this meta-analysis and systematic review, we conducted a search in PubMed, Medline, Embase, and Cochrane for all the clinical studies in which bivalirudin was compared to heparin as the procedural anticoagulant in percutaneous peripheral interventions. Outcomes studied included all-cause mortality, all-bleeding, major and minor bleeding, and access site complications. Results: Eleven studies were included in the analysis, totaling 20,137 patients. There was a significant difference favoring bivalirudin over heparin for all-cause mortality (risk ratio 0.58, 95% CI 0.39–0.87), all-bleeding (risk ratio 0.62, 95% CI 0.50–0.78), major bleeding (risk ratio 0.61, 95% CI 0.39–0.96), minor bleeding (risk ratio 0.66, 95% CI 0.47–0.92), and access site complications (risk ratio 0.66, 95% CI 0.51–0.84). There was no significant difference in peri-procedural need for blood transfusions (risk ratio 0.79, 95% CI 0.57–1.08), myocardial infarction (risk ratio 0.87, 95% CI 0.59–1.28), stroke (risk ratio 0.77, 95% CI 0.59–1.01), intracranial bleeding (risk ratio 0.77, 95% CI 0.29–2.02), or amputations (OR 0.75, 95% CI 0.53–1.05). Conclusion: Our meta-analysis suggests that bivalirudin use for percutaneous peripheral interventions is associated with lower all-cause mortality, bleeding, and access site complications as compared to heparin. Further large randomized trials are needed to confirm the current results.
- 1 December 2018
- Published by SAGE Publications in Vascular
- Vol. 27 (1) , 78-89
Bivalirudin versus heparin in patients undergoing percutaneous peripheral interventions: A systematic review and meta-analysis
Background: Bivalirudin may be an effective alternative anticoagulant to heparin for use in percutaneous peripheral interventions. We aimed to compare the safety and efficacy of bivalirudin versus heparin as the procedural anticoagulant agent in patients undergoing percutaneous peripheral intervention. Methods: For this meta-analysis and systematic review, we conducted a search in PubMed, Medline, Embase, and Cochrane for all the clinical studies in which bivalirudin was compared to heparin as the procedural anticoagulant in percutaneous peripheral interventions. Outcomes studied included all-cause mortality, all-bleeding, major and minor bleeding, and access site complications. Results: Eleven studies were included in the analysis, totaling 20,137 patients. There was a significant difference favoring bivalirudin over heparin for all-cause mortality (risk ratio 0.58, 95% CI 0.39–0.87), all-bleeding (risk ratio 0.62, 95% CI 0.50–0.78), major bleeding (risk ratio 0.61, 95% CI 0.39–0.96), minor bleeding (risk ratio 0.66, 95% CI 0.47–0.92), and access site complications (risk ratio 0.66, 95% CI 0.51–0.84). There was no significant difference in peri-procedural need for blood transfusions (risk ratio 0.79, 95% CI 0.57–1.08), myocardial infarction (risk ratio 0.87, 95% CI 0.59–1.28), stroke (risk ratio 0.77, 95% CI 0.59–1.01), intracranial bleeding (risk ratio 0.77, 95% CI 0.29–2.02), or amputations (OR 0.75, 95% CI 0.53–1.05). Conclusion: Our meta-analysis suggests that bivalirudin use for percutaneous peripheral interventions is associated with lower all-cause mortality, bleeding, and access site complications as compared to heparin. Further large randomized trials are needed to confirm the current results.
- 1 August 2017
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 28 (5) , 395-405
Direct Xa inhibitors in addition to antiplatelet therapy in acute coronary syndrome
We carried out a meta-analysis summarizing the efficacy and safety of direct factor Xa inhibitor (DXI) in patients receiving guideline-based antiplatelet therapy (GBAT) after an acute coronary syndrome. Randomized-controlled trials have shown that the addition of a DXI to GBAT after acute coronary syndrome can reduce ischemic events, the trade-off being an increase in major bleeding complications. PubMed, Central, Embase, The Cochrane Register, Google Scholar databases, and the scientific session abstracts were searched for eligible randomized trials from 1 January 1990 through 31 December 2016. Nine randomized-controlled trials were included in this meta-analysis enrolling a total of 45651 patients. There was a significant reduction in major adverse cardiovascular events with DXIs/GBAT compared with GBAT alone [odds ratio (OR): 0.88; 95% confidence interval (CI): 0.82–0.94, number needed to treat=52]. There were also significant reductions in two individual components of major adverse cardiovascular events: myocardial infarction (OR: 0.89; 95% CI: 0.81–0.98) and stent thrombosis (OR: 0.73; 95% CI: 0.59–0.90), favoring the DXI/GBAT group. There was an increased risk of major bleeding (OR: 2.51; 95% CI: 1.82–3.46) and intracranial hemorrhage (OR: 3.47; 95% CI: 1.76–6.86) compared with GBAT. In acute coronary syndromes, the addition of a DXI to GBAT results in a significant reduction of major adverse cardiovascular events, myocardial infarction, and stent thrombosis, offset by an increased risk of bleeding.
- 1 August 2017
- Published by Wolters Kluwer Health in Coronary Artery Disease
- Vol. 28 (5) , 395-405
Direct Xa inhibitors in addition to antiplatelet therapy in acute coronary syndrome
We carried out a meta-analysis summarizing the efficacy and safety of direct factor Xa inhibitor (DXI) in patients receiving guideline-based antiplatelet therapy (GBAT) after an acute coronary syndrome. Randomized-controlled trials have shown that the addition of a DXI to GBAT after acute coronary syndrome can reduce ischemic events, the trade-off being an increase in major bleeding complications. PubMed, Central, Embase, The Cochrane Register, Google Scholar databases, and the scientific session abstracts were searched for eligible randomized trials from 1 January 1990 through 31 December 2016. Nine randomized-controlled trials were included in this meta-analysis enrolling a total of 45651 patients. There was a significant reduction in major adverse cardiovascular events with DXIs/GBAT compared with GBAT alone [odds ratio (OR): 0.88; 95% confidence interval (CI): 0.82–0.94, number needed to treat=52]. There were also significant reductions in two individual components of major adverse cardiovascular events: myocardial infarction (OR: 0.89; 95% CI: 0.81–0.98) and stent thrombosis (OR: 0.73; 95% CI: 0.59–0.90), favoring the DXI/GBAT group. There was an increased risk of major bleeding (OR: 2.51; 95% CI: 1.82–3.46) and intracranial hemorrhage (OR: 3.47; 95% CI: 1.76–6.86) compared with GBAT. In acute coronary syndromes, the addition of a DXI to GBAT results in a significant reduction of major adverse cardiovascular events, myocardial infarction, and stent thrombosis, offset by an increased risk of bleeding.
- 1 September 2016
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 64 (3) , 862
High-Risk Carotid Plaque Characteristics and Implications for Carotid Stenting
- 1 September 2016
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 64 (3) , 862
High-Risk Carotid Plaque Characteristics and Implications for Carotid Stenting
- 1 July 2016
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 34, 32-33
Neurocognitive Outcomes and Microembolization Rates Following Carotid Artery Angioplasty and Stenting In Symptomatic Patients
- 1 July 2016
- Published by Elsevier in Annals of Vascular Surgery
- Vol. 34, 32-33
Neurocognitive Outcomes and Microembolization Rates Following Carotid Artery Angioplasty and Stenting In Symptomatic Patients
- 1 October 2015
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 221 (4) , S178-S179
Effects of Pharmacotherapeutic Agents on Microembolization Rates During Carotid Revascularization
- 1 October 2015
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 221 (4) , S178-S179
Effects of Pharmacotherapeutic Agents on Microembolization Rates During Carotid Revascularization